Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy
Lingegowda S. Mangala, … , David G. Gorenstein, Anil K. Sood
Lingegowda S. Mangala, … , David G. Gorenstein, Anil K. Sood
Published October 20, 2016
Citation Information: JCI Insight. 2016;1(17):e87754. https://doi.org/10.1172/jci.insight.87754.
View: Text | PDF | Expression of Concern | Corrigendum
Research Article Angiogenesis Oncology

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy

  • Text
  • PDF
Abstract

Current antiangiogenesis therapy relies on inhibiting newly developed immature tumor blood vessels and starving tumor cells. This strategy has shown transient and modest efficacy. Here, we report a better approach to target cancer-associated endothelial cells (ECs), reverse permeability and leakiness of tumor blood vessels, and improve delivery of chemotherapeutic agents to the tumor. First, we identified deregulated microRNAs (miRs) from patient-derived cancer-associated ECs. Silencing these miRs led to decreased vascular permeability and increased maturation of blood vessels. Next, we screened a thioaptamer (TA) library to identify TAs selective for tumor-associated ECs. An annexin A2–targeted TA was identified and used for delivery of miR106b-5p and miR30c-5p inhibitors, resulting in vascular maturation and antitumor effects without inducing hypoxia. These findings could have implications for improving vascular-targeted therapy.

Authors

Lingegowda S. Mangala, Hongyu Wang, Dahai Jiang, Sherry Y. Wu, Anoma Somasunderam, David E. Volk, Ganesh L. R. Lokesh, Xin Li, Sunila Pradeep, Xianbin Yang, Monika Haemmerle, Cristian Rodriguez-Aguayo, Archana S Nagaraja, Rajesha Rupaimoole, Emine Bayraktar, Recep Bayraktar, Li Li, Takemi Tanaka, Wei Hu, Cristina Ivan, Kshipra M Gharpure, Michael H. McGuire, Varatharasa Thiviyanathan, Xinna Zhang, Sourindra N. Maiti, Nataliya Bulayeva, Hyun-Jin Choi, Piotr L. Dorniak, Laurence J.N. Cooper, Kevin P. Rosenblatt, Gabriel Lopez-Berestein, David G. Gorenstein, Anil K. Sood

×

Figure 4

Therapeutic efficacy of CH/Endo28-NPs in a HeyA8 ovarian cancer orthotopic mouse model.

Options: View larger image (or click on image) Download as PowerPoint
Therapeutic efficacy of CH/Endo28-NPs in a HeyA8 ovarian cancer orthotop...
Seven days following tumor cell injection, mice were randomly divided into 6 groups (9–10 mice per group) to receive 1 of the following 6 therapies: (i) CH/Endo28-control miR inhibitor, (ii) CH/Endo28-control miR inhibitor + paclitaxel, (iii) CH/Endo28-miR106b-5p inhibitor, (iv) CH/Endo28-miR106b-5p inhibitor + paclitaxel, (v) CH/Endo28-miR30c-5p inhibitor, or (vi) CH/Endo28-miR30c-5p inhibitor + paclitaxel. Mice were sacrificed when any animals in a control or treatment group became moribund (after 3 to 4 weeks of therapy). (A) Mean tumor weight. (B) Mean number of tumor nodules. (C) Representative images of tumor burden from at least 5 mice per group. (D) Representative tumor sections showing effect of miR silencing on pericyte coverage. Tumor sections were stained with anti-desmin (pericyte coverage marker) and anti-CD31 (for blood vessels) antibodies respectively (red indicates blood vessels, green indicates pericyte coverage, and blue indicates nuclei). (E) Representative tumor sections showing effect of miR silencing on vascular permeability of blood vessels after i.v. injection of FITC-dextran. Tumor sections were stained with anti-CD31 antibody (red indicates blood vessels, green indicates FITC-dextran, and blue indicates nuclei). In D and E, staining was done on 5 sections per group. (F) Determination of extent of hypoxia after staining tumor sections with hypoxia marker anti-CA9 and anti-CD31 antibodies (red indicates blood vessels, green indicates hypoxia, and blue indicates nuclei). (G) Quantification of pericyte coverage and extravasated FITC-dextran. Pericyte coverage was determined by the percentage of vessels with ≥ 50% coverage of desmin in positive cells in 5 random fields of each section at ×200 magnification of each tumor. Quantification of extravasated FITC-dextran was carried out using fluorescence microscopy under the green fluorescent filter using the following scoring system: 0 points, no staining; 1 point, <25%; 2 points, 25%–50%; 3 points, 50%–75%; 4 points, 75%–100% FITC-dextran (using 8–10 sections per tumor at ×200 magnification. (H) Quantification of average number of blood vessels after indicated treatments. To quantify microvessel density, we recorded the number of blood vessels that stained positive for CD31 in 5 random fields of each section at ×200 magnification for each sample. Values are the mean ± SEM. *P < 0.05, **P < 0.01, (1-way ANOVA followed by a Tukey’s multiple comparison post-hoc test). NS, not significant. Scale bars: 100 μm. CH., chitosan; miR-inh, miRNA inhibitor.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts